Skip to content
Boost Up Blog – Lifestyle
Author:
Olema Oncology
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2026
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
May 26, 2026
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
May 22, 2026
Olema Oncology to Participate in Upcoming Investor Conferences
May 21, 2026
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
May 20, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
April 29, 2026
eX² Technology Announces Long-Term Dark Fiber Agreement on Navajo County Middle-Mile Network, Strengthening Strategic Southwest Connectivity Corridor
April 29, 2026
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
April 21, 2026
1
2
Next Page
→